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In this study, a cell-penetrating peptide, the transactivating transcriptional factor (TAT) domain from HIV, was linked to a
chitosan/doxorubicin (chitosan/DOX) conjugate to form a chitosan/DOX/TAT hybrid. The synthesized chitosan/DOX/TAT
conjugate showed a different intracellular distribution pattern from a conjugate without TAT. Unlike both free DOX and the
conjugate without TAT, the chitosan/DOX/TAT conjugate was capable of efficient cell entry. The chitosan/DOX/TAT conjugate
was found to be highly cytotoxic, with an IC50 value of approximately 480 nM, 2 times less than that of chitosan/DOX (980
nM). The chitosan/DOX/TAT provided decreases in tumor volume of 77.4 and 57.5% compared to free DOX and chitosan/DOX,
respectively, in tumor-bearing mice. Therefore, this study suggests that TAT-mediated chitosan/DOX conjugate delivery is
effective in slowing tumor growth.
Water soluble polymers, including N-(2-hydroxypropyl)-
methacrylamide (HPMA) copolymers1,2 and polysaccharides
such as cyclodextrin,3 are frequently applied as drug carriers
as they have the ability to improve the solubility of hydro-
phobic compounds. This in turn increases the therapeutic
index of low-molecular-weight drugs by raising drug payloads
per molecule of polymer, improves the stability of conjugated
drug molecules4 and enhances the drug’s tumor retention
capability, known as the EPR effect.5 Over the past two deca-
des, the concept of using water-soluble polymers as drug car-
riers has been proposed and validated by several research
groups, including Kopecek et al.4 and Duncan.6 The intracel-
lular delivery of polymeric drug carriers, however, has been a
challenge due to their large size and inherently poor penetra-
tion capabilities. Furthermore, the endocytotic or phagocytic
uptake characteristic of such macromolecules directs these
polymers to the endosomes, where they are susceptible to en-
zymatic and acidic degradation. Recently, a series of peptides
named protein transduction domain (PTD) peptides,7–9 such
as the peptide from the transactivating transcriptional factor
(TAT) protein of HIV, have been discovered and extensively
investigated. PTDs can translocate across almost all types of
eukaryotic plasma membranes through a seemingly energy-
independent pathway. In addition, following chemical hybrid-
ization to other macromolecules or even nanoparticulates,
PTDs can transduce these linked species into cells and tissues
and even cross the blood-brain barrier (BBB), a highly imper-
meable barrier in the body.9 The BBB comprises endothelial
cells of the brain tissue capillaries. The endothelial cells are
connected by tight junctions and form an epithelial-like,
high-resistance barrier.10 Our previous reports also demon-
strated that the PTD peptide successfully delivered protein
molecules into cells in vitro and in vivo, thereby enhancing
diagnostic or therapeutic activity compared with proteins not
hybridized to the PTD.11–13 The objective of this research
was to examine whether PTDs (in particular TAT) could
improve the intracellular localization of polymeric drugs
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composed of chitosan and doxorubicin (DOX). Chitosan is
the N-deacetylated derivative of chitin and has been utilized
as a drug14,15 or gene carrier16–18 due to its biomedical
advantages, including biocompatibility and biological activity.
In addition, the reactive amino groups in the backbone of
chitosan make it possible to chemically conjugate various bio-
logical molecules, such as growth factor and antibody.19,20
DOX has been used as the drug of choice in cancer therapy
but has produced undesirable side effects, such as cardiotox-
icity, due to a wide tissue distribution, including the heart.21
Therefore, DOX incorporation into polymeric drug carriers,
such as nanoparticles22,23 or micellar carriers,24,25 has been
attempted in experimental cancer therapies. However, non-
specific drug leakage from the carrier also evokes side effects;
thus, direct conjugation to the carrier has been alternatively
attempted. Mitra et al.22 attempted DOX and dextran cou-
pling and then encapsulated the DOX-dextran conjugate in
chitosan hydrogel nanoparticles to reduce the side effects of
DOX.
The direct conjugation between chitosan and DOX has
not yet been attempted in other studies. Although the poly-
meric anticancer drug conjugates can create an enhanced
permeability and retention (EPR) effect in the tumor, they
have limited tumor localization activity. In this study, a PTD
was introduced into chitosan/DOX conjugates to achieve
increased tumor penetration by the PTD and to create
enhanced tumor localization of the polymeric drug conjugate.
A sulfhydryl group was introduced to the amine moieties in
chitosan, and then, DOX was conjugated via SMCC to chito-
san. Finally, TAT was conjugated to chitosan/DOX via the
formation of a disulfide bond. In this report, we describe the
synthesis of chitosan/DOX/TAT conjugates, their internaliza-
tion into cells and the antitumor activity of the conjugates
in vitro and in vivo.
Material and Methods
Materials
Chitosan was purchased from Fluka (St. Louis, MO). Doxo-
rubicin and MTT were purchased from Sigma Aldrich (St.
Louis, MO). Fetal bovine serum (FBS), phosphate-buffered
saline (PBS), 0.25% (wt/vol) trypsin-EDTA, RPMI-1640
medium, Dulbecco’s Modified Essential Medium (DMEM),
a-Minimum Essential Medium (a-MEM) and penicillin/
streptomycin antibiotics were from Gibco-BRL (Gaithersburg,
MD). N-succinimidyl-S-acetylthiopropionate (SATP) and the
bifunctional cross-linkers, 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (EDC) and N-succinimidyl-3-(2-
pyridyldithio) proprionate (SPDP), were obtained from Pierce
(Rockford, IL). CT-26 adenocarcinoma cells were obtained
from the American Type Culture Collection (Manassas, VA).
The PTD TAT (CGGGYGRKKRRQRRR) was chemically
synthesized using an automatic peptide synthesizer based on
F-moc chemistry. The prepared peptide was further purified
using HPLC. The underlined sequence of the TAT peptide is
the core sequence of the peptide responsible for membrane
transduction. Another four amino acid residues were added
at the N-terminus of the peptide to introduce a sulfhydryl (-SH)
group (cysteine) for conjugation to chitosan and to enhance
the flexibility of the peptide (GGG sequence). All other
chemicals used were of analytical grade.
Synthesis of chitosan/DOX/TAT conjugates
Chitosan solution [m.w. 2000, 1 mg/mL in PBS (pH 7.4, 1.05
mM KH2PO4, 155 mM NaCl and 2.9 mM Na2HPO47H2O)]
was allowed to react with N-succinimidyl S-acetylthiopropio-
nate (SATP, 50 mM in PBS; Pierce) and was then reacted
with 50 mM hydroxylamine solution (10 mM EDTA in PBS)
to generate the sulfhydryl group in chitosan. The unreacted
SATP was removed by ultrafiltration using a 1.0-K molecular
weight cutoff membrane. The sulfhydryl content was assayed
using Ellman’s Reagent (Pierce) according to the manufac-
turer’s instructions. The chitosan/DOX conjugate was gener-
ated by linking the sulfhydryl groups in chitosan and DOX
with a heterobifunctional crosslinker, succinimidyl 4-(N-mal-
eimidomethyl) cyclohexane-1-carboxylate (SMCC; 50 mM in
PBS; Pierce). A volume of 20 lL of triethylamine and 300 lL
of SMCC (18 mg/ml in DMSO) were added to the DOX so-
lution (0.2 mg/mL in PBS, pH 8). The mixture was incubated
at room temperature for 2 h. After adjusting the pH of the
mixture to 5.5, 2 mL of sulfhydryl chitosan solution was
added (1.5 mg/mL in PBS). The mixture was incubated at
room temperature for 2 h and then kept at 4C overnight.
The free DOX, SMCC and triethylamine were removed from
the chitosan/DOX solution via ultrafiltration using a 1.0-K
molecular weight cutoff membrane. After adjusting the pH of
the chitosan/DOX solution to 5.5, the TAT peptide (1.0 mg/
0.2 mL PBS) was added. The mixture was incubated at room
temperature for 2 h and then kept at 4C overnight. The chi-
tosan/DOX/TAT conjugates were separated from free chito-
san, chitosan/DOX and TAT by passing the mixture through
a HiTrap heparin affinity column connected to a FPLC with
a gradient elution containing a 2.0 M NaCl solution.23 Elu-
tion profiles were determined by absorbance at 280 nm. The
column was eluted at a flow rate of 1 mL/min, while the
NaCl gradient was increased at a rate of 50 mM/min. Salts
in the collected chitosan/DOX/TAT conjugate fraction were
removed by passing the sample through a desalting column
and washing with PBS. Successful production of the chitosan/
DOX/TAT conjugate was confirmed by SDS-PAGE.
Flow cytometric analysis
The cells were seeded at a density of 1  106 cells per well in
six-well plates in 1.5 mL culture medium. One day later, the
cells were washed and incubated with DOX, chitosan/DOX
or chitosan/DOX/TAT conjugates (0.2 lM) for 30 min at
37C in humidified 5% CO2. To study cell internalization in
the presence of serum, the peptides were dissolved in DMEM
in the absence of serum, followed by the addition of 10%
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extensively with trypsin-EDTA to remove surface-bound con-
jugates and washed again. The cells were then fixed with 1%
paraformaldehyde and washed with PBS. Analysis was con-
ducted on a FACScaliber flow cytometer (Becton Dickinson,
San Jose, CA) equipped with a 635-nm red dye laser. The
fluorescence of 5,000 vital cells was acquired, and data were
visualized in logarithmic mode.
Confocal microscopic observation of
chitosan/DOX/TAT internalization
The cultivation of the CT-26 colon adenocarcinoma cell line
was conducted as described previously.13 Cells were plated on
Lab-Tek (4-well) chamber slides (Nalgene Nunc Interna-
tional, Napervile, IL) at a density of 1  104 cells/1.8 cm2
and incubated at 37C in a humidified 5% CO2 atmosphere.
After complete adhesion, the culture medium was removed.
The chitosan/DOX conjugate or chitosan/DOX/TAT conju-
gate was then added to the cells at a final concentration of
0.2 lM. Following a 30-min incubation at 37C in a humidi-
fied 5% CO2 atmosphere, the cells were extensively washed
and fixed in 1% (wt/vol) paraformaldehyde in PBS for 20
min at room temperature. Nuclear staining was conducted
with Hoechst 33342 (5 lg/ml; Molecular Probes) according
to the manufacturer’s protocol. Coverslips were mounted
onto slides using ProLong Gold (Molecular Probes). Confocal
microscopy was carried out using an inverted LSM 510 laser
scanning microscope (Carl Zeiss, Gottingen, Germany)
equipped with a Plan-Apochromat 63, 1.4 N.A. or 40, 1.4
N.A. lens. The laser was set at 358 nm (blue) and 543 nm
(orange) to produce the excitation wavelengths for DAPI and
rhodamine, respectively. Z-series were taken of a 1- to 2-lm
optical section at 2-lm intervals.
Cytotoxicity assay
Evaluation of the cytotoxicity of each conjugate was con-
ducted using the MTT assay. In general, the CT-26 cells were
seeded at a density of 1.0  104 cells/well in a 96-well flat-
bottomed microassay plate (Falcon, Becton Dickinson, Frank-
lin Lakes, NJ) and incubated for 24 h. Fluorescence intensity
measurements of doxorubicin in the chitosan/DOX and chi-
tosan/DOX/TAT conjugates, DOX/TAT and free DOX solu-
tions were used to determine and adjust the drug concentra-
tions. DOX/TAT conjugate was synthesized according to a
previous report.11 The conjugates were then added in varying
concentrations to the culture media, and the mixture was
incubated for another 72 h at 37C. At the end of the experi-
ment, the medium was replaced with 200 lL of fresh DMEM
medium without serum, and 120 lL of 2 mg/ml MTT solu-
tion in PBS was added. After incubation for an additional 4
h at 37C, the MTT-containing medium was removed, and
200 lL of dimethyl sulfoxide was added to dissolve the form-
azan crystals formed by the live cells. The absorbance of the
solution in each well was measured by a microplate reader
(Bio-Tek, Winooski, VT) at a wavelength of 540 nm. Cell
viability (%) was calculated according to the following
equation:
Cell viability (%) ¼ (absorbance of cells treated with each
conjugate/absorbance of cells not treated with each conju-
gate)  100.
In vivo distribution and antitumor effect of
chitosan/DOX/TAT conjugates
Five-week-old female BALB/c mice were purchased and
housed in the Animal Care Facilities in Seoul National Uni-
versity. BALB/c mice bearing subcutaneous tumors were used
as an animal model for evaluation of the tissue distribution
and anticancer activity of the chitosan/DOX/TAT conjugate.
To measure the tissue distribution of the applied samples,
including chitosan/Dox and chitosan/Dox/TAT, 50 lL
samples were injected via peritumoral injection, followed by
dissection of the tumor 12 h after injection. The optimum
cutting temperature-mounted frozen sections were prepared
and then examined with a confocal microscope. The serum
was collected and its volume measured, followed by homoge-
nization and measurement of fluorescence using a spectro-
photometer. In addition, tissues including the liver, heart,
spleen, kidney and lung were dissected, weighed and homo-
genized, and their fluorescence was measured using a
spectrofluorometer (FP-6500; JASCO, Tokyo, Japan). The
fluorescence was expressed as a percentage of injected dose
per gram of tissue.
To generate tumors, 5-week-old BALB/c mice were subcu-
taneously injected in the right hind flank with 100 lL of a
single-cell suspension containing 4  106 CT-26 cells. Tumor
size was measured with Vernier calipers for the largest
(length) and smallest (width) superficial visible diameters of
the protruding tumor mass through the skin. Tumor volumes
were calculated according to the following formula: volume
¼ 0.52  W2  L, where W and L represent the width and
length, respectively.24 Treatment of the tumors was started 2
weeks after tumor implantation, when their size reached
about 100–150 mm3. Test compounds included (i) PBS solu-
tion (control); (ii) DOX (100 lM); (iii) chitosan/DOX (100
lM); and (iv) chitosan/DOX/TAT conjugate (100 lM DOX
equivalent). Each experimental group contained eight mice.
The mice were treated (50 lL volume) nine times over 15
days via peritumoral injection. Tumor volumes were mea-
sured at 3–4-day intervals. At the end of the observation
period, the mice were sacrificed and autopsied. The tumors
were removed, weighed and fixed with formalin.
Statistical analysis
All measurements were conducted in triplicate and expressed
as the mean 6 standard deviation. The Student’s t test was
performed to compare the statistical significance of the
in vitro cytotoxicity, in vivo antitumor effects and biodistri-










2472 Cell-penetrating conjugates for cancer therapy
Int. J. Cancer: 128, 2470–2480 (2011) VC 2010 UICC
Results
Synthesis of chitosan/DOX/TAT
The reactive amino groups in the backbone of chitosan ena-
ble coupling with various bioactive molecules, including pep-
tides and drugs, and antibodies.25–28 The scheme for chito-
san/DOX/TAT conjugate synthesis is shown in Figure 1. The
amino groups of chitosan were reacted with SATP to create
a sulfhydryl group (-SH), followed by coupling with the
SMCC-activated DOX. Chitosan/DOX conjugates were linked
to a well-documented PTD, the TAT peptide, through the
thiol group of the cysteine residue already introduced in the
TAT peptide. Chitosan/DOX/TAT conjugates were formed
through a stable disulfide bond. Because chitosan and DOX
were linked via noncleavable covalent bonds using the cross-
linking agent SMCC, the conjugates were stable throughout
the entire cell translocalization process. The addition of the
CGGG sequence between chitosan and the TAT peptide
ensured the maximal maintenance of the cell-penetrating ac-
tivity of TAT peptide. Unreacted doxorubicin, chitosan, TAT
peptide, chitosan/DOX and chitosan/DOX/TAT conjugates
were eluted from the heparin column via a linear elution
using 2.0 M NaCl according to published methods.13 Peak III
in Figure 2a had the same retention time as pure TAT pep-
tide and, thus, was identified as unreacted TAT peptide. Col-
lected peaks I to III were subjected to SDS-PAGE (Fig. 2b).
Free doxorubicin was loaded in lane 1, and collected peaks I
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to III were loaded into lanes 2–4. The molecular weights of
chitosan and TAT are 2,000 Da and 1,700 Da, respectively.
Coomassie dyes bind to proteins through interactions with
an arginine residue, aromatic amino acids and histidine.29
The bands in lanes 1 (doxorubicin) and 2 (chitosan/DOX)
were not stained strongly by Coomassie blue, but the band in
lane 4 (TAT) was clearly stained. The molecular weight of
the band in lane 3 (chitosan/DOX/TAT conjugates) was
about 4,000 Da and was stained more clearly than the band
in lane 2. The band in lane 3 thus demonstrated that chito-
san/DOX/TAT conjugates were successfully linked.
Intracellular delivery of the chitosan/DOX conjugate
is mediated by the TAT peptide
The cell permeability of the chitosan/DOX/TAT conjugate
was compared with those of unconjugated DOX and the chi-
tosan/DOX conjugate lacking the TAT peptide. As shown by
the FACS results (Fig. 3a), during the 30-min incubation, the
ability of chitosan/DOX/TAT to translocate was significant
when compared to the conjugate lacking TAT and free dox-
orubicin. The free doxorubicin transduced into cells slightly
better than did the chitosan/DOX conjugates.
The intracellular distribution pattern of the chitosan/
DOX/TAT conjugate was observed by confocal microscopy
(Fig. 3b). Although both free doxorubicin and the chitosan/
DOX/TAT conjugate penetrated into CT-26 cells, different
intracellular distributions were observed for these two com-
pounds. The free DOX diffused only slightly into the cells,
and the few internalized molecules accumulated in the nuclei
due to their low molecular weight. In contrast, most of the
chitosan/DOX/TAT conjugates displayed cytoplasmic local-
ization as opposed to endosomal localization or simply
adsorption onto the cell surface (Fig. 3b).
In vitro cytotoxic activity of the
chitosan/DOX/TAT conjugates
The anticancer activity of the conjugates in the cells, i.e., the
cytotoxicity of the conjugate, was measured using chitosan/
DOX, chitosan/DOX/TAT and free DOX in CT-26 colon
adenocarcinoma cells in a log-phase culture (Fig. 4). The
Figure 2. (a) Purification and characterization of chitosan/DOX/TAT conjugates by heparin affinity column chromatography; (b) SDS-
polyacrylamide gel electrophoresis. Lanes 1, 2, 3 and 4 of the SDS-PAGE show DOX, chitosan/DOX, chitosan/DOX/TAT and free TAT,
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Figure 3. (a) FACS analysis of the cell uptake of DOX, chitosan/Dox and chitosan/DOX/TAT conjugates into the CT-26 cell line (1  106 cells/
well). Control (purple peak) cells. DOX (red peak), chitosan/DOX (blue peak), chitosan/DOX/TAT (green peak) treated cells. Data obtained from
triplicate experiments with at least four samples (n ¼ 4). (b) Cellular localization of DOX, chitosan/DOX and chitosan/DOX/TAT in CT-26
adenocarcinoma cells. Cellular localization was monitored by confocal microscopy. The conjugates were visualized with DOX (orange), and the
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chitosan/DOX/TAT conjugate was much more potent than ei-
ther the free DOX or the chitosan/DOX conjugate in killing
CT-26 cells. The cytotoxicity of chitosan/DOX/TAT was signifi-
cant at 500 nM (p ¼ 0.0013), 1,000 nM (p ¼ 0.0004) and
2,000 nM (p ¼ 0.0037) compared to that of chitosan/DOX. The
IC50 (inhibitory concentration 50%) value (as measured by the
MTT assay) of the chitosan/DOX/TAT conjugate was approxi-
mately 480 nM, which was about 2 times less than that of chi-
tosan/DOX (980 nM) and 4 times less than that of free DOX.
In contrast, the IC50 of the chitosan/DOX conjugate (980 nM)
was 1.5 times less than that of free doxorubicin. The IC50 of the
DOX/TAT conjugate was 822 nM, which was higher than that
of chitosan/DOX/TAT and lower than that of chitosan/DOX.
In vivo tumor regression activity of the
chitosan/DOX/TAT conjugates
To confirm that the chitosan/DOX/TAT conjugates actually
penetrate into tumors, the conjugates were applied in vivo. The
tumor tissues from chitosan/DOX/TAT-treated mice displayed a
strong and uniform red staining due to DOX on the conjugates
(Fig. 5a). Conversely, mice injected with chitosan/DOX dis-
played a sporadic and weak staining of DOX (Fig. 5b). The flu-
orescence in other organs, including the liver, heart, spleen, kid-
ney, lung and serum, were examined for the possibility of
nonspecific distribution of chitosan/DOX conjugates. The conju-
gates of chitosan/DOX/TAT displayed higher fluorescence in
the tumor, followed by the kidney (Fig. 5c). The uptake of chi-
tosan/DOX/TAT in the tumor (p ¼ 0.0013) was significantly
higher than that of chitosan/DOX conjugate; however, it
decreased in the kidney (p ¼ 0.0122) and liver (p ¼ 0.0073).
To assay the biological consequences of treating subcuta-
neous solid tumors with chitosan/DOX/TAT, conjugates were
injected into the peritoneal cavities of test samples (Fig. 6).
Pooled data from multiple experiments revealed that treat-
ment with chitosan/DOX/TAT resulted in a substantial
reduction in tumor mass in all mice. In comparison, tumors
treated with free DOX or chitosan/DOX were larger than
their TAT-conjugated counterparts in all mice. As can be
seen, tumors continued to grow in control mice injected with
PBS solution, and the average volume of the excised tumors
reached from 1,200 to 7,500 mm2 during 2 weeks and 4
weeks of treatment. In contrast, tumor growth in the mice
treated with chitosan/DOX/TAT conjugate showed consider-
able regression and significantly reduced to 900 mm2 (range
between 600 and 1,900 mm2).
Tumor volume following treatment with the chitosan/
DOX/TAT conjugate showed a significant decrease at 20
days (p ¼ 0.0037), 24 days (p ¼ 0.0242), 27 days (p ¼
0.0031) and 30 days (p ¼ 0.0127) compared to tumor volume
following treatment with the chitosan/DOX conjugate.
Discussion
Drug therapies, especially anticancer drug therapies, are hin-
dered by two major obstacles. One obstacle is the lack of
preferential target cell killing, whereas the other is the poor
translocalization through cell membranes. The first hurdle
can be overcome by applying a combination of prodrug and
targeting approaches using antibodies.30–32 To resolve the
second limitation, the most established method is to use re-
ceptor-mediated endocytosis or phagocytosis,33 despite seri-
ous setbacks such as low uptake efficiency34 and the need for
drug release from endosome.35 At present, few delivery sys-
tems are capable of overcoming these two limitations, and
none of them provides evidence of macromolecular drug
delivery such as proteins or genetic materials. Therefore, a
highly effective delivery system, particularly for hydrophilic,
macromolecular drug types, is imperative, and the quest
remains. In this regard, PTDs or cell-penetrating peptides,
corresponding to short 30-residue synthetic peptides, are the
most promising strategy to overcome both extracellular and
intracellular limitations to the administration of various bio-
molecules, including proteins,35 polymeric drugs36 and even
solid nanoparticulates.8
The polymer-drug conjugate exhibits decreased clearance
and prolonged circulation, thereby providing sufficient time for
the polymer-drug conjugate to accumulate at the target site
and precluding the undesirable side effects generated by free
drug.37 However, macromolecular drug delivery systems are
internalized by the cells through endocytosis, which might
impede trafficking to subcellular targets.4 Therefore, PTDs have
been applied to aid internalization of macromolecular drug
Figure 4. Cytotoxicity due to DOX (n), chitosan/DOX (l), chitosan/
DOX/TAT (~) and DOX/TAT (!) in CT-26 colon adenocarcinoma
cells in log-phase culture. The amount of cells remaining was
assessed by an MTT assay and then compared with those of
untreated cells in the control wells. Data obtained from triplicate
experiments with at least four samples (n ¼ 4) are presented as
mean 6 SD. *p < 0.05, as compared to chitosan/DOX at the same
concentration. [Color figure can be viewed in the online issue,
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conjugates. Herein, the authors applied TAT peptides as the
PTD for the internalization of chitosan/DOX conjugates. The
translocation and intracellular distribution patterns of chitosan/
DOX/TAT into cells were demonstrated by FACS and confocal
microscopy, respectively (Figs. 3 and 4). The translocation of
chitosan/DOX/TAT was significant when compared to the con-
jugate lacking TAT and free DOX. The free DOX transduced
into cells slightly better than did the chitosan/DOX conjugates.
Different intracellular distributions were observed for both free
DOX and the chitosan/DOX/TAT conjugate, although both
free DOX and the chitosan/DOX/TAT conjugate penetrated
into CT-26 cells (Fig. 4). The chitosan/DOX conjugates were
not transduced into the cytosol due to their increased molecu-
lar weight. It has been shown that positively charged polymers,
such as chitosan and polylysine, are transduced into cells via
adsorption-mediated endocytosis,38 which is in agreement with
our current results regarding the distribution of chitosan/DOX
conjugates. The conjugates with TAT attached, however, dem-
onstrated a cytoplasmic distribution rather than an endoplas-
mic retention. From the enhanced distribution of these mole-
cules in the tumor tissues, we expected an increased antitumor
effect from the chitosan/DOX/TAT conjugates. Almost all of
the chitosan/DOX/TAT conjugates were found inside the cell,
specifically in the cytosol of the CT-26 cells (Fig. 4). In agree-
ment with results previously reported for TAT- or other PTD-
Figure 5. Tumor distribution into the colon cancer of (a) chitosan/DOX/TAT and (b) chitosan/DOX. The left panel indicates the fluorescent image of
the conjugate in the tumor tissues, whereas the right panel was an identical DIC mode picture. (c) The organ distribution of the chitosan/DOX/TAT
conjugate and chitosan/DOX measured at 12 h after injection. *p < 0.05, as compared to chitosan/DOX in the same organ. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 6. Tumor volume was determined by caliper measurements
taken twice per week and averaged for each treatment group (see
Materials and Methods section). DOX (n), chitosan/DOX (l),
chitosan/DOX/TAT (~) and PBS (!). *p < 0.05, as compared to
chitosan/DOX at the same time. [Color figure can be viewed in the
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linked protein conjugates,39,40 further incubation of the cells
with the TAT conjugate resulted in the localization of the con-
jugates into the nucleus (data not shown).
The chitosan/DOX/TAT conjugate was much more effective
than the free DOX, chitosan/DOX conjugate or DOX/TAT
conjugates in killing CT-26 cells (Fig. 5). The anticancer activ-
ity of chitosan/DOX/TAT demonstrated that the covalent link-
ing to TAT was able to successfully transduce otherwise endo-
cytosable polymeric drugs into cancer cells for potential
therapeutic purposes. This rapid intracellular transduction of
chitosan/DOX/TAT was able to cause significant cytotoxic
effects in CT-26 cells, as demonstrated by a much lower IC50
value. In a previous study, DOX/TAT conjugates were more
potent in killing drug resistant MCF-7 cells than free DOX.11
In this study, the IC50 of chitosan/DOX/TAT was 480 nM, the
IC50 of DOX/TAT was 820 nM and the IC50 of chitosan/DOX
was 980 nM. The introduction of TAT to free DOX makes it
more cytotoxic than attaching chitosan to free DOX. When
both chitosan and TAT were conjugated to free DOX, there
was a significant IC50 lowering effect. In a previous study, the
TAT-protein conjugate had a considerably lower IC50 concen-
tration than did that of the antibody-protein conjugate that
mediates endocytosis.13,41,42 The superior cytotoxicity of the
chitosan/DOX/TAT conjugate was apparently due to the
increased cell-internalization efficiency of TAT, overcoming the
endocytic machinery of the cell and also overcoming the
increased retention time in cells by the EPR effect of chitosan.
Concerning the EPR effect, attempts have been made to gener-
ate polymeric carriers in combination with small and free anti-
cancer drugs with some success. Eliaz et al.43 reported that
doxorubicin encapsulated in targeted liposomes was more effi-
cient in killing murine melanoma cells than was free doxorubi-
cin. They reported that kinetic profile of antitumor toxicity by
the free DOX reached noticeable regression of tumor cells 96 h
after the treatment, which maintained similar extent of toxicity
level (i.e., % cell survival). In comparison, liposome with DOX
loading was faster than free DOX to reach the noticeable tumor
cell regression, as similar regression of cell survival by the lipo-
somal DOX was obtained 12 h after the treatment. Liposome
carrier has difference in the payloads of active drug, i.e., 1 unit
of liposomal carrier presents much higher DOX equivalence
than free DOX, providing faster tumor killing activity. Poly-
meric carrier also possesses similar characteristics to liposome
carrier in terms of high drug loading. Therefore, based on this
report,43 polymeric DOX was anticipated to follow similar
kinetics to liposome and present marked cytotoxicity.
In our study, chitosan/DOX/TAT conjugates penetrated into
the cells within 30 min, as demonstrated by FACS analysis and
confocal microscope observation. Although the author per-
formed the cytotoxicity test for 1 day, the chitosan/DOX/TAT
conjugates might affect the cell cytotoxicity regardless of the
culture period. In addition, the tumor distribution also clearly
indicated the fast translocalization of the chitosan/DOX/TAT
conjugate in the tumor compared to the chitosan/DOX over 12
h (Fig. 6). Although the chitosan/DOX conjugate by itself could
create an EPR effect, the slow distribution to the tumor with
increased kidney, liver, heart and serum uptake demonstrated a
less effective antitumor activity compared to that with the TAT
conjugate. Therefore, in vitro cytotoxicity and in vivo antitumor
activity of both conjugates demonstrated different results.
The subcutaneous tumor mass was substantially reduced by
treatment with chitosan/DOX/TAT conjugates compared to
treatment with free DOX or chitosan/DOX. It is probable that
the efficiency in tumor regression could be partly due to the
high cytosolic localization of the TAT-linked chitosan/DOX,
which was then able to exert its maximum antitumor effects.
The antitumor effect of chitosan/DOX/TAT resulted from the
significantly enhanced concentration of the chitosan/DOX/TAT
conjugates in the tumor tissue over other organs (Fig. 7).
In vivo tumor regression result by the treatment using chi-
tosan/DOX/TAT was far more convincing than by in vitro
cellular IC50 results, which already provided evidence of con-
jugate the anticancer activity by the same conjugate. The in
vitro cytotoxicity was primarily due to the hydrolyzed DOX
from the backbone of chitosan and chitosan/TAT. A small
molecular drug such as DOX is able to penetrate a single cell
layer, as confirmed by confocal observation. The cellular cy-
totoxicity was not highly influenced by the presence of TAT
in the backbone of chitosan. However, in vivo conditions
recruited dense tumor tissue, which was hard to penetrate
compared to the single cell membrane; therefore, the TAT
could exert its own penetrating capacity in the in vivo condi-
tion, demonstrating a marked antitumor result as compared
with that obtained in the in vitro study. The tumor penetra-
tion capacity of PTD conjugates has been previously reported
by the authors.13 The in vitro transduction results determined
for the chitosan/DOX/TAT conjugate and the in vivo tumor
regression induced by the conjugate suggest TAT-mediated
transduction. The TAT-mediated, chitosan-based approach
offers significant advantages over the antibody- or other re-
ceptor-based delivery systems for the delivery of small drugs.
Indeed, this chitosan system inherits all of the advantages of
polymer-based systems for delivering small drugs, such as
high drug loading and stabilizing effects.4,6,15 Yet, this system
is still able to achieve active drug targeting and superefficient
cellular drug uptake, in contrast to the slow uptake encoun-
tered with particulate-based delivery systems. In addition, the
hydrophilic nature of TAT and chitosan could render hydro-
phobic drugs more soluble and bioavailable, whereas the abil-
ity of TAT to transport all drug types could render mem-
brane-impermeable hydrophilic drugs cytotoxic. Moreover,
the polymeric architecture of the chitosan-based system
delivers high drug payloads, thereby increasing the cytotoxic
activity for the same drug concentration. Because the conju-
gate displays rapid cell uptake, the findings of this study
open up possibilities for the treatment of cancers. In sum-
mary, both the in vitro and in vivo results demonstrate that
TAT-conjugated chitosan/DOX is potent in regressing tumor
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